Stephen Robertson
Patrimonio netto: 9 M $ in data 31/07/2026
Patrimonio netto: 9 M $ in data 31/07/2026
Stephen P.
Robertson is Secretary, Chief Legal & Compliance Officer at Kezar Life Sciences, Inc. since 2026.
Mr. Robertson is Secretary, Chief Legal Officer & Chief Compliance at Aurinia Pharmaceuticals, Inc. since 2014.
Formerly, Mr. Robertson was a Partner at Borden Ladner Gervais LLP from 2014 to 2020.
Education includes graduate studies at the University of Manitoba and undergraduate studies at Simon Fraser University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/08/2026 | 600.787 ( 0,47% ) | 9 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| AURINIA PHARMACEUTICALS INC. | Responsabile della Conformità | 02/11/2020 |
| KEZAR LIFE SCIENCES, INC. | Responsabile della Conformità | 11/05/2026 |
| Società | Posizione | Fine |
|---|---|---|
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01/01/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Simon Fraser University
Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manitoba
University of Manitoba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aurinia Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics | Health Technology |
Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapies targeting protein homeostasis | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale